Share on LinkedInShare on LinkedIn

ARTICLE · 23 JULY 2024

Reaffirming Standards: Bioavailability V. Therapeutic Efficacy And Coverage V. Disclosure

Lakshmikumaran & Sridharan
Lakshmikumaran & Sridharan
Contributor
Lakshmikumaran & Sridharan

Lakshmikumaran & Sridharan

Lakshmikumaran & Sridharan (LKS) is a premier full-service Indian law firm specializing in areas...

View firm profile
Explore more from Lakshmikumaran & Sridharan

In India, patent applications filed for new forms of known chemical entities have always faced strict scrutiny under the provisions of Section 3(d) of the Indian Patents Act, 1970 (‘Act').

IndiaIntellectual Property

Background:

In India, patent applications filed for new forms of known chemical entities have always faced strict scrutiny under the provisions of Section 3(d) of the Indian Patents Act, 1970 ('Act'). The judgement delivered by the Divisional Bench of the Delhi High Court presided by two justices, Hon'ble Justice Vibhu Bakhru and Hon'ble Justice Amit Mahajan on 24 April 2024, provided critical interpretations for some of the most disputed matters concerning the field of patenting new chemical entities (NCEs) and its forms, such as salts. The judgment which was issued in the case of Natco Pharma v. Novartis Ag and Anr.1 reasserted the landmark decision that was made in the matter of Novartis v. UoI2. This case revolved around the interpretation of 'enhanced efficacy' under Section 3(d) of the Act. The Divisional Bench's decision focused on following two pivotal issues under a broader question of a credible challenge to the validity of a patent:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from